Every benefits review published last year asked the same three questions. Does it integrate with your EHR? What is the wait time? What does it cost per employee per month?
None of them asked the harder question: who profits when your employees use it, and who loses?
After two decades in benefits systems, I can tell you the part most reviews skip: telemedicine bundled into a health plan at zero copay can raise total system costs instead of lowering them.
How Bundled Telemedicine Makes Money
Most major carriers now bundle telemedicine as a value-add benefit. Zero copay for employees, $2 to $4 per employee per month for you. Reviews praised this as democratizing healthcare access.
What they missed is the business model. Bundled telemedicine platforms earn revenue well beyond the monthly fee, in four steps.
Step 1: A virtual visit generates a prescription. In one Cleveland Clinic analysis of more than 88,000 urgent care visits for respiratory infections, 58 percent of virtual visits ended with an antibiotic, compared with 43 percent of in-person visits.
Step 2: The prescription routes through the carrier's affiliated pharmacy benefit manager.
Step 3: The PBM earns on spread pricing, rebate retention, and formulary steering. Ohio's Medicaid audit put the average spread at $5.71 per prescription, and the spread on generics at 31 percent.
Step 4: Some platforms also collect referral or data-sharing compensation.
The telemedicine visit is the loss leader. The pharmacy revenue is the margin.
The Total Cost of a Visit
The published per-visit fee hides most of the cost. A RAND analysis of commercial claims for acute respiratory illness found the virtual visit itself is cheap, about half the cost of an office visit and under 5 percent of an emergency department visit. The problem is what happens around it: 88 percent of direct-to-consumer telehealth visits represented new utilization that would not otherwise have occurred, and net annual spending on acute respiratory illness rose by $45 per telehealth user.
Add the prescription side. A new visit that routes a drug through an affiliated PBM keeping a spread of about $5.70 per script, while steering toward brand drugs, looks like savings at the copay while the plan absorbs the rest. The per-employee fee you can see is the smallest line item. The claims and pharmacy spend you cannot see are the largest.
The Data in the Fine Print
Reviews celebrated platforms for EHR integration and care-coordination features. Integration is real, and it is not neutral. Many platform contracts include data-sharing provisions that do three things:
- Feed utilization patterns back to carriers for future underwriting
- Flag high-cost members for care-management programs
- Generate care-gap alerts that steer employees toward higher-cost specialty referrals inside the carrier's network
The effect shows up in the renewal. A platform that pushes utilization up and routes downstream care into the carrier's network is doing its job, but its job is not the same as yours. It gets paid on utilization. You are accountable for the total claims number.
Mental Health and Prescription Incentives
Nearly every review highlighted expanded mental health access as a major win: licensed therapist visits, psychiatry consultations, 24/7 crisis support.
Access is a real win. The incentive question is separate. What share of your virtual psychiatry visits end in a new prescription, and which drugs do they choose? If you cannot answer that, the platform is answering it for you.
The fastest-growing category is ADHD medication for adults. During the pandemic, regulators waived the in-person evaluation requirement for controlled stimulants, and telehealth-only companies moved in quickly. The Drug Enforcement Administration has investigated some of these firms over stimulant prescribing practices, and an IQVIA analysis published by the DEA shows a sharp rise in stimulant prescriptions during the telehealth expansion.
The drug cost question matters because brand and generic pricing sit far apart. Pharmacy price trackers put brand-name ADHD stimulants at roughly $220 to over $1,000 a month, while generics run $15 to $70. A platform that steers toward brand fills is quietly deciding your pharmacy budget.
Misaligned Incentives
- Platform: paid on visit completion rate
- Provider: paid per visit, a productivity model
- PBM: paid on prescription volume and brand selection
- You: accountable for outcomes and total cost
Only one party on that list is measured on actual health improvement. The other three are measured on activity. Nothing in that structure rewards keeping a patient in therapy over moving them to a monthly prescription, and nothing penalizes a platform when medication spend climbs without a measured change in symptoms. The platform reports rising engagement. The plan pays rising claims.
What Reviews Should Have Asked
Critical Question #1: Who Owns the Pharmacy Route?
If your telemedicine platform is bundled through your carrier or has preferred pharmacy partnerships, a conflict of interest is baked into every prescription. Demand in writing:
- Full disclosure of any PBM-platform relationship
- Average prescription generation rate by visit type
- Spread-pricing transparency on telemedicine-originated scripts
- The contractual right to route prescriptions through your own PBM
Critical Question #2: What Happens to Your Data?
Every platform collects chief complaints, diagnostic impressions, prescription history, utilization patterns, and biometric data. Require contractual protection for:
- Data ownership rights
- A prohibition on sharing with underwriters
- Limits on automatic care-management enrollment
- Annual data portability rights
If the contract cites quality improvement as the reason for data sharing but never defines the term, the platform is mining your data.
Critical Question #3: What's the Total Episode Cost?
A telemedicine visit triggers downstream expenses that the per-visit fee never answers:
- Referrals, often in-network only, which limits price competition
- Diagnostic testing, and where the platform steers those orders
- Prescription refills, possibly locked into 90-day mail order
- Follow-up visits, whether virtual or pushed to higher-cost urgent care
Reviews rank platforms on the fee you can see. Total-episode math ranks them on the spend you cannot. The RAND study is the clearest illustration: a virtual visit for acute respiratory illness cost about half as much as an office visit, yet net spending still rose $45 per user because the visits added new utilization. A cheap visit that creates a downstream prescription and a follow-up is not a cheap episode.
Utilization Economics vs. Prevention Economics
Most telemedicine reviews operate under utilization economics: the assumption that more access means better outcomes, which means lower costs. That logic produced sky-high premiums, PBM profit extraction, and wellness programs that added screenings without moving outcomes.
Prevention runs on different logic. Fewer acute visits mean fewer prescriptions, fewer episodes, and lower total claims. WellthCare, the first Health-to-Wealth Benefit System, was built on that logic: by automatically rewarding every verified preventive action with spendable Store dollars and automatic retirement contributions, it turns prevention into the most financially rewarding choice for employees and the lowest-cost choice for employers. That lowers costs and enables wealth building.
Telemedicine is valuable only when it prevents the need for future telemedicine. A platform that treats a sinus infection is processing an expensive transaction. A platform that spots allergic rhinitis patterns and connects the employee to long-term management is creating value. You cannot see that difference in a review focused on wait times and satisfaction scores.
How WellthCare Does It Differently
At WellthCare, we do not bundle telemedicine as a utilization driver. We integrate preventive care access as part of our Health-to-Wealth Operating System:
- Prevention first: Employees earn Store dollars for completing preventive actions that avoid acute telemedicine visits. The best visit is the one that never happens.
- Transparent pharmacy routing: When prescriptions are needed, routing is transparent, and pharmacy savings are passed through instead of retained by intermediaries.
- Data builds wealth, not risk profiles: Healthcare data triggers Store rewards and automatic retirement contributions, not premium increases or automatic enrollment in high-cost programs.
- Aligned incentives: The best clinical decision is also the best financial decision for employees, employers, and providers.
We measure success by total cost of care reduction and outcome improvement, not visit volume or engagement metrics.
When Telemedicine Does Save Money
None of this is an argument against virtual care. Telemedicine lowers total cost when it replaces something more expensive. Cigna's analysis of its MDLIVE visits put the savings at $93 to $141 per visit, depending on whether the visit substituted for a primary care appointment, a specialist, or an urgent care trip, and found 19 percent fewer emergency and urgent care visits among telehealth users.
The distinction is substitution versus addition. RAND found that only 12 percent of direct-to-consumer telehealth visits replaced another visit; 88 percent were new utilization. A virtual visit that keeps someone out of the emergency room saves real money. A virtual visit that adds a prescription on top of care that would not otherwise have happened does not.
Ask your platform to report substitution visits and new-utilization visits separately, and to show episode costs for each. That single report separates a money-saving tool from a money-adding one.
Your Action Plan
Audit Your Current Contract
Request 24 months of data broken down by:
- Condition type
- Prescription generation rates
- Downstream referrals
- Total episode costs, not just visit fees
Calculate your true per-employee cost including pharmacy and referral expenses.
Demand Contractual Protection
Before signing or renewing, require:
- Prescription transparency: monthly reporting of generation rates, pharmacy costs, and all PBM and pharmacy relationships
- Data quarantine: an explicit prohibition on sharing utilization data with underwriters or auto-enrolling employees in carrier programs
- Total cost measurement: platform reports downstream costs for 90 days after each visit, with performance penalties if episode costs exceed benchmarks
- Incentive disclosure: how are providers compensated, which partnerships generate platform revenue, and who owns preferred referral networks
Track the Right Metrics
Monitor monthly:
- Prescription generation rate by visit type
- Average pharmacy cost per telemedicine visit, the full PBM cost, not the copay
- Referral rate to specialists
- Total cost per episode by condition
- Changes in urgent care and ER utilization
Red flags:
- Prescription rates well above the clinical norm for acute conditions
- High referral rates to high-cost specialists
- Rising pharmacy costs concurrent with rising telemedicine use
- Increasing visit volume without a matching decrease in other utilization
Evaluate Total System Cost and Incentive Alignment
Last year's telemedicine reviews missed the story that mattered: the incentive architecture. Telemedicine platforms are economic actors whose business models can conflict with your cost-containment goals. Stop evaluating telemedicine as a benefit feature and start evaluating it as a risk-management tool. The right platform reduces your total claims spend, lowers your future underwriting risk, improves employee health outcomes measurably, and increases your negotiating leverage.
Until employers evaluate on total system cost, outcome improvement, and incentive alignment, the industry will keep celebrating innovations that quietly extract wealth while claiming to build health. The problem is a system that rewards utilization over prevention. Until that changes, every review will keep missing the question that matters: who profits when your employees get sick, and who loses when they get well?
Ready to explore a benefits system where healthcare builds employee wealth instead of extracting it? Learn how WellthCare's Health-to-Wealth Operating System aligns incentives across preventive care, pharmacy, and retirement, with no rip-and-replace disruption.
Have you tracked total episode costs for your telemedicine platform, or only per-visit fees? What hidden costs have you discovered? Share your experience in the comments.